dossier,guideline,type of study,pdf link,Endpoints: Observations: clinical examiniation ,Endpoints: Observations: gross pathology ,Endpoints: Observations: microscopic pathology ,Endpoints: LC50,Endpoints: LC50 unit (mg/l or ppm),Endpoints: 95% confidence interval ,Endpoints: LC50 male,Endpoints: LC50 female,Endpoints: moribund or dead animals prior to study termination,Endpoints: mortality rate ,Endpoints: conclusion,Test method: Test substance: pH and adjustment,Test method: Test substance: physical form ,Test method: Test substance: treatment prior to use,"Test method: Test substance: particle size, distribution, shape and density",Test method: Test substance: actual concentration (%),Test method: Test substance: purity (%),Test method: Test substance: chemical batch nr,Test method: Test substance: additional info,Test method: Test animals: species/strain,Test method: Test animals: source,Test method: Test animals: Age: age value at start of experiment ,"Test method: Test animals: Age: age unit ( days, weeks, months, years)",Test method: Test animals: Weight: male mean weight value ,Test method: Test animals: Weight: female mean weight value ,"Test method: Test animals: Weight: mean weight unit (g, kg)",Test method: Test animals: sex,Test method: Test animals: housing and feeding,Test method: Test animals: n animals / group,Test method: Test condition: nominal dose levels value,Test method: Test condition: nominal dose levels unity,Test method: Test condition: actual dose levels value,Test method: Test condition: actual dose levels unit,Test method: Test condition: Inhalation exposure: Exposure apparatus: design ,Test method: Test condition: Inhalation exposure: Exposure apparatus: type,Test method: Test condition: Inhalation exposure: Exposure apparatus: dimension,Test method: Test condition: Inhalation exposure: Exposure apparatus: source of air,Test method: Test condition: Inhalation exposure: air flow rate,"Test method: Test condition: Inhalation exposure: oro-nasal, head only, whole body",Test method: Test condition: exposure time (hour),Test method: Test condition: observation period (day),Test method: Test condition: Equipment measuring: humidity,Test method: Test condition: Equipment measuring: temperature,Test method: Test condition: Equipment measuring: particle size and concentration,Reliability: SCCS comment to test,Reliability: year,Reliability: control groups,Reliability: GLP,Reliability: limit test ,Reliability: klimisch score,Reliability: ref. in dossier,additional information,own comments
zinc pyrithione,OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_133.pdf,"all surviving animals showed signs of toxicity (one of the two surviving females exposed to 1.82 mg/l showed stiffness in the hind legs) which improved until the end of the observation period. except one female exposed to 0.53 mg/l, normal bodyweight development was observed during the second week.","lung abnormalities (swelling, pallor, abnormally dark appearance, dark patches and foci) and liver changes (dark appearance) were observed in animals that died. except one female exposed to 0.53 mg/l, no abnormalities were observed in animals that were killed at the end of the observation period.",,0.84,mg/l,,1.34,1.03,yes,all deaths occurred on day 1 after exposure as follows: 1 of 5 males and 0 of 5 females at 0.53 mg/l; 3 of 5 males and 2 of 5 females at 0.95 mg/l; 5 of 5 males and 3 of 5 females at 1.82 mg/l.,the results of this study lead to classification as acute tox 3; H331 (toxic if inhaled) according to CLP (Regulation (EC) No 1272/2008) by the registrant. ,,aerosol dust,,"mmadss: 3.3, 3.5, 3.8 μm ",,,tox 1000 ,"test substance: zinc pyrithion, label: zinc-pyrion",rat/sprague-dawley,,,,,,,f & m,,10,"0.53, 0.95, 1.82",mg/l,,,,,,,,nose only,4,14,,,,this study shows that systemic effects on hind legs might occur after inhalation exposure. ,1996,,yes,,,e2,,
polysilicone-15,OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_024.pdf,"there were no clinical signs during or after the inhalation exposure in group 1. in group 2, clinical signs were only seen from the day after the exposure. the clinical signs consisted of restlessness and ruffled fur, both findings slight to marked in degree, and of tachypnea and hunched posture and were followed by premature death or had cleared within 3 to 5 days in the one survivor of this group. this survivor remained free from clinical signs from five days after exposure onwards. there were no relevant, adverse effects on body weight development in the survivors of groups 1 and 2.","necropsy did not reveal any macroscopic pathology changes in any of the survivors either of group 1 or group 2. in the two decedents of group 1 the lungs were dark red discoloured and incompletely collapsed, and in the nine decedents of group 2 the lungs were dark red discoloured. ",,0.285 --> 1.838,mg/l,,,,yes,"in group 1, two of ten animals were found dead on the day after the exposure. in group 2 nine of ten animals were found dead, one or two days after exposure.","no lc50 of parsol slx was calculated from this study, but was estimated to be between 0.285 and 1.838 mg/l air.",,,"at ambient temperature, the test substance was too viscous for aerosol generation. therefore, the test material was to a temperature of 55°C prior to nebulisation.",,,,,,rat/han wistar,,,,,,,f & m,,10,,,"0.285, 1.838 ",mg/l ,flow-past,,,,,nose only,4,15,,,"two gravimetric measurements of particle size distribution produced mmad and gsd of 2.64 µm (gsd 2.63) and 3.03 µm (gsd 2.49) for group 1, and 2.67 µm (gsd 2.74) and 2.66 µm (gsd 2.73) for group 2. ",,,,yes,,,"9 (subm.2), 12(subm.2)",the generated aerosol at chemically determined mean concentrations of 0.285 mg/l air (group 1) or 1.838 mg/l air (group 2) ,
"1,3,5-triazine, 2,4,6-tris(1,1'-biphenyl)-4-yl-",OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_070.pdf,"clinical signs attributable to treatment with the aqueous placebo dilution or test item dilution did not occur and no premature deaths occurred during the study. in balf collected at about 14 hours after end of exposure the total cell count (mainly macrophage and neutrophil numbers), TNFα and total protein were considerably higher in both sexes of test item-treated animals than in placebo control animals, while total protein levels in plasma did not distinguish the two groups. the changes in balf were consistent with the histopathology findings of granulocytic infiltration in alveolar wall and lumen, diffuse alveolar histiocytosis and alveolar lining cell activation seen in all test item-treated animals assigned to interim pathology at approximately 24 hours post end of exposure (test day 2). increases of total cell count, TNFα and total protein in balf and of absolute and relative lung weight, and the histopathology findings of granulocytic infiltration, diffuse alveolar histiocytosis and alveolar lining cell activation seen in the test item group on test day 2 were attributed to the treatment with the test item. increase in neutrophil numbers in balf on test day 2 was considered to be indicative of an inflammatory reaction. the study authors considered the findings noted in test item-treated animals on test day 2 to represent an acute clearance reaction to the lung burden of test item. this is further supported by the absence of these findings by test day 15. this response is well documented for particle exposures to lung (stone et al. 2007) and the cellular response is not characteristic of immunologic response profiles reflected in the low numbers of lymphocytes at day 2 and their absence histologically at day 15 (holt, p. et al. 2008) .",,,> 0.4976,mg/l,,,,no,,"the applicant argued that such pulmonary inflammatory responses are not expected with use of eth50 in sunscreens or other products from spray-on dispensers. spray applicators are generally pump-type dispensers with some increase in marketed products using fine-spray aerosol type dispensers. in each of these applicators, the droplet sizes (aerosol) are designed to be at least 30 times larger than those used in this rat inhalation test. according to durand et al. (2007), sunscreen sprayable formulations should be dispensed with droplet size of more than 30 µm (mmad) with not more than 1% of droplets of aerodynamic diameter at or below 10 µm. the authors concluded that for nanosized eth50 the inhalation lc50 is greater than the highest technically achievable aerosol concentration level of 4.976 mg formulation/L air, or greater than 0.4976 mg eth50/L air, according to this study’s results with mmad of about 1.2 µm. a notable but reversible lung inflammatory response occurred which is considered a normal non-allergenic type response to particle exposures.",,,"the test item and the placebo were prepared as aqueous dilutions at a ratio (w/w) of 20% fat65’080/f or 20% fat65’080-placebo plus 80% purified water, the tarhet concentration as active ingredient of uv filter eth50 was 10%",nano-sized material. d(0.5)=109 nm. ,10,,lot04122fc7,"test substance: fat 65'080/f. concentration: 47.6 % of the active uv filter eth50,  the target concentration as active ingredient of uv filter eth50 was 10%",rat/ wistar [hanrcc:wist(spf)] ,,,,,,,f & m,,30,0.4976,mg/l,0.602,mg/l ,flow-past,,,,,nose only,4,14,,,the particle size distribution was determined twice during each exposure using a mercer 7 stage cascade impactor (model 02-1300). two gravimetric measurements of particle size distribution during exposure indicated mass median aerodynamic diameters (mmads) and geometric standard deviations (gsd) of 1.23 µm (gsd 2.13) and 1.27 µm (gsd 2.19).,"the observed effects are similar to those observed upon inhalation of particulate materials in general including some nano-particles. however, the massive influx of neutrophils and the increase of macrophages by approximately a factor 2 cannot be considered to be merely a mild inflammation after inhalation of particles. none of the results in the cited reference stone et al. 2007 supports this conclusion. in contrary, these results presented here clearly indicate a strong inflammatory response of the host. the fact that even on day 15 a few parameters differed from those of the controls confirms this strong adverse reaction after inhalation of eth50 (109).","an additional group of 15 males and 15 females was exposed to an aqueous dilution of the control item, fat 65’080placebo, at aerosol generation conditions similar to those used for the test item ",,yes,,,5 (subm 3),"the first satellite group was sacrificed about 14 hours post end of exposure for bronchoalveolar lavage fluid (balf) and plasma sampling, the second group was assigned to interim pathology at approximately 24 hours post end of exposure (test day 2), and the third was assigned to pathology at 14 days post exposure (test day 15). all animals were observed for clinical signs and mortality during and following the inhalation exposure, i.e. until interim sacrifice or over a 15-day observation period. body weights were recorded before exposure on test day 1 in all animals and during the observation period on test days 4, 8 and 15 in all animals assigned to be sacrificed on day 15. the BALF examinations comprised total and differential cell counts and the determination of total protein, TNF-α and IL-6. in addition, total protein was determined in blood plasma from the animals assigned to balf sampling. pathology examinations comprised complete macroscopic pathology, the determination of lung weight and histopathology of the lungs and tracheobronchial lymph nodes on days 2 and 15.  test item: mmad: 1.2 µm; median droplet volume cm³: 9.05E-19; number of particle a.i./L: 1.15E+12; approx. surface area (m²) / L: 0.0275. placebo: MMAD: 1.08 µm; median droplet volume cm³: 6.60E-19; number of particle a.i./L: --; approx. surface area (m²) / L: --.",
"1-hydroxyethyl-4,5-diamino pyrazole sulfate",OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_079.pdf,"treatment-related effects included a slight to moderate decreased breathing frequency during exposure,  and discolouration of the fur of the animals, which was visible from just after exposure until necropsy 14 days later.","grey discoloured areas on the lungs in half of the animals at necropsy,",,5.24,g/m3,,,,no,,in rats the 4 h lc50 value of an aerosol of the test substance was larger than 5.24 g/m³ for both sexes,,,the test material was milled before use to obtain an mmad in the range of 1-4 µm.  ,mmad in the range of 1-4 µm. the mass median aerodynamic (mmad) size of the particles in the test atmosphere was 3.3 µm and the distribution of particle sizes had a geometric standard deviation of 1.8.,,99.8 ,et046,test substance: 18247 pyrazol ,rat/wistar (crl:[wi]wu br),,,,,,,f & m,,10,5.24 ± 0.31,g/m³,,,,,,,,,4,14,,,the mass median aerodynamic (mmad) size of the particles in the test atmosphere was 3.3 µm and the distribution of particle sizes had a geometric standard deviation of 1.8.,,,,yes,,,16,,
Decamethylcyclopentasiloxane,OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_174.pdf,The food consumption and mean body weights were decreased in animals exposed to concentrations of 6.73 mg D5/l (434 ppm) and above but these effects were reversible during the observation period. the clinical signs that were observed following exposure were of low incidence. ,"In animals dying spontaneously post exposure, the lungs were affected (red lungs partly collapsed) while no macroscopic observations were recorded in any animals necropsied at the scheduled sacrifice date. no animals died at the lowest exposure concentration. ",,8.67 ,mg d5/L (560 ppm),,,,yes,"at the intermediate exposure concentrations, four animals of each sex died. all animals at the highest exposure concentration died during the exposure phase.",the LC50 for both sexes was calculated to be 8.67 mg d5/L (560 ppm). ,,,,,,,,,rat/Fischer 344 ,,test substance: D5,,,,,f&m,,10,,,"4.64, 6.73, 9.82, 15.37 ","mg/l (300, 434, 634, 1000 ppm)",,,,,,whole body,4,15,,,,"the concentration used is above the saturated vapour concentration (139 ppm or 2.1 mg/l) and therefore a proportion of the test substance would have been inhaled as an aerosol, rather than a vapour. based on the available data, theLC50 of D5 in rats was calculated to be 8.67 mg (560 ppm).",,,yes,,,15,"taken from sccs 1241/10. four groups of 5 male and 5 female fischer 344 rats were exposed by whole body inhalation to d5 during a single, continuous 4-hour period, followed by an observation period of 15 days. ",
Decamethylcyclopentasiloxane,OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_174.pdf,,,,,,,,,no,,all animals survived a single four hour whole body vapour exposure of >545 ppm of D5 with no overt signs of toxicity and no mortality.,,,,,,,,,rat/Wistar,,test substance: D5,,,,,f&m,,10,>545,ppm,,,,,,,,whole body,4,,,,,"the concentration used is above the saturated vapour concentration (139 ppm or 2.1 mg/l) and therefore a proportion of the test substance would have been inhaled as an aerosol, rather than a vapour. based on the available data, theLC50 of D5 in rats was calculated to be 8.67 mg (560 ppm).",,,,,,16,,
Cetylpyridinium chloride,OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_171.pdf,"test atmosphere of 0.05 mg/l: all animals gained body weight over the 14-day observation period. following exposure, clinical observations observed for four animals included reduced faecal volume and hypoactivity, but recovered by day 3 and appeared active and healthy for the remainder of the 14-day observation period. test atmosphere of 0.5 mg/l: toxic signs noted prior to death included abnormal respiration, abnormal posture, and hypoactivity. the surviving female exhibited similar clinical signs as well as reduced faecal volume, but recovered by day 7 and appeared active and healthy for the remainder of the 14-day observation period. although this animal lost weight through day 7, it gained body weight over the 14-day observation period.  ",test atmosphere of 0.05 mg/l: no gross abnormalities were noted for any of the animals when necropsied at the conclusion of the 14-day observation period. test atmosphere of 0.5 mg/l: gross necropsy of the decedents revealed discoloration and oedema of the lungs and mucous-filled tracheas. no gross abnormalities were noted for the euthanised animal when necropsied at the conclusion of the 14-day observation period.,, 0.054 -->  0.51,mg/l,,,,yes,none in the 0.05 mg/l group; all five males and four females died within three days of exposure to the test atmosphere of 0.5 mg/l,"under the conditions of this study, the acute inhalation LC50 of cetylpyridinium chloride was between 0.054 and 0.51 mg/l in male and female rats.",,,,,,100,Lot #00217966,test substance: cetylpyridinium chloride,"rat/ sprague-dawley derived, albino",,,,,,,f & m,,10,"0.05, 0.5",mg/l,,,,,,,,nose only,4,14,,,"chamber concentration and particle size distributions of the test atmosphere were determined periodically during each exposure period. test atmosphere of 0.05 mg/l: the gravimetric and nominal chamber concentrations were 0.054 and 0.14 mg/l, respectively, and the mass median aerodynamic diameter was estimated to be 2.8 μm. test atmosphere of 0.5 mg/l: the gravimetric and nominal chamber concentrations were 0.51 and 1.24 mg/l, respectively, and the mass median aerodynamic diameter was estimated to be 2.9 μm.","overall SCCS comment to acute toxicity studies: the studies on acute oral, dermal and inhalation toxicity described above and performed according to currently accepted test guidelines are the studies included in the company submission but not in submission ii. submission ii includes several studies of older date and generally not performed according to currently accepted test guidelines; these studies have not been evaluated in this opinion as the more recent studies performed according to currently accepted test guidelines are considered to be more reliable.",2005,,yes,,,19,,
dihydroxyacetone,OECD 403,in vivo ,https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_048.pdf ,"Body weights were recorded prior to exposure on test day 1, and during the observation period on test days 4, 8 and 15. on day 15, all animals were sacrificed and necropsied. there were no clinical signs and no relevant adverse effects on body weight development.",,no macroscopic pathology findings.,> 5.114,mg/l,,,,no,,the LC50 of DHA in rats obtained in this study was estimated to be > 5.114 mg/l/4h. ,,,,,,99.7,VL 157850,test substance: dihydroxyacetone,rat/wistar,,,,,,,f & m,,10,5,mg/l,5.114,mg/l,flow-past inhalation exposure ,,,,,"nose-only,",4,14,,,gravimetric measurements of particle size distribution during the exposure produced mass median aerodynamic diameters of 2.92 µm and 2.96 µm.,,2004,,yes,,,14,,